TG Therapeutics Inc

2026-10-07 20:01; UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

2026-10-06 20:00; UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

2026-10-05 20:06; UTC

TG Therapeutics Inc. shares fell sharply, pulling back from Friday's close after earlier reaching a session high, amid multiple year-end catalysts.

2026-10-02 19:26; UTC

TG Therapeutics is trading higher amid social media buzz over a buy recommendation and an $86 price target for its anti-CD20 treatment, Briumvi.

2026-10-01 23:05; UTC

TG Therapeutics Inc is trading modestly higher in after-market hours, despite remaining below its 20-day moving average after three consecutive sessions finishing lower.

2026-09-30 20:07; UTC

TG Therapeutics Inc shares fell modestly following Tuesday's close, amid a broader market decline, and are currently near the midpoint of their one-month trading range.

2026-09-28 20:07; UTC

TG Therapeutics Inc shares are declining, continuing a downward trend since Friday's close amid a broader market downturn, despite a brief recovery attempt.

2026-09-25 21:01; UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick and moving lower from Friday's close, despite remaining above its 20-day moving average.

2026-09-24 23:45; UTC

TG Therapeutics Inc declined in after-market hours on Thursday, moving from a larger drop to a more modest decrease while remaining above its 20-day moving average.

2026-09-23 23:01; UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick, despite strong U.S. economic data indicating robust growth in the private sector.

2026-09-22 22:06; UTC

TG Therapeutics Inc saw a slight decline in after-market trading, despite recent strength, as economic data showed a contraction in manufacturing activity.

2026-09-21 19:16; UTC

TG Therapeutics shares are advancing as discussions highlight BRIUMVI's growing momentum and market share gains in the IV anti-CD20 market for relapsing multiple sclerosis.

2026-09-18 20:06; UTC

TG Therapeutics is trading modestly higher, rebounding after an earlier pullback, and has now finished higher for three consecutive sessions.

2026-09-17 19:54; UTC

TG Therapeutics Inc is moving higher as economic data shows unexpected labor market strength, despite a decline in housing starts.

2026-09-16 23:56; UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

2026-09-15 23:41; UTC

TG Therapeutics shares are lower in after-market trading amid negative market sentiment. The New York Empire State Manufacturing Index fell sharply, raising investor caution.

2026-09-14 19:16; UTC

TG Therapeutics Inc shares are lower today amid broader market declines. CEO Weiss highlighted upcoming catalysts, including a significant treatment administration method.

2026-09-11 20:08; UTC

TG Therapeutics shares are declining during Friday's session, despite social media optimism about its subcutaneous BRIUMVI formulation and potential Priority Review Voucher benefits.

2026-09-10 20:31; UTC

TG Therapeutics Inc shares are lower in after-market trading, reflecting a decline despite starting the session near the top of their one-month range.

2026-09-09 20:07; UTC

TG Therapeutics shares are lower today amid cautious outlook from CEO Weiss and mixed analyst sentiment on sales estimates. Earlier, the stock pulled back from session highs.

2026-09-04 20:07; UTC

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

2026-09-03 20:07; UTC

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2026-09-02 20:02; UTC

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

2026-09-01 19:54; UTC

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

2026-08-31 22:16; UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

2026-08-28 19:51; UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

2026-08-27 23:41; UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

2026-08-26 19:16; UTC

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

2026-08-25 23:36; UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.

2026-08-24 23:21; UTC

TG Therapeutics Inc shares are higher in after-market hours, reflecting positive momentum following Monday's close, despite no specific news driving the movement.